Literature DB >> 26720202

Gastric Cancer: Preoperative TNM Staging With Individually Adjusted Computed Tomography Scanning Phase.

Cen Shi1, Bo Liu, Jing Yan, Huanhuan Liu, Zilai Pan, Weiwu Yao, Fuhua Yan, Huan Zhang.   

Abstract

OBJECTIVE: The aim of this study was to evaluate test bolus scan technology on preoperative diagnostic performance, vascular enhancement, and artery visualization for gastric cancer.
METHODS: The institutional review board approved this study. Fifty-four patients in protocol 1 were resigned to a fixed delay time scan method, and their images were obtained in the late arterial phase (AP) and portal venous phase (PP), with start delays of 40 and 70 seconds, respectively. Fifty-six patients in protocol 2 had undergone the test bolus method first and received the time to peak enhancement of the aorta. Their images were obtained in the AP and PP with start delays in the time to peak enhancement and 20 seconds after the AP, respectively. Two radiologists performed consensus interpretation of the preoperative TNM staging, vascular enhancement, tumor contrast-to-noise ratio (CNR) and artery visualization between the 2 protocols.
RESULTS: There is no significant difference in the T, N, and M staging diagnostic accuracy between the protocols (P = 0.41, P > 0.99, and P = 0.34, respectively). For serosa-negative (T1, T2, and T3) tumors, the diagnostic accuracy obtained with protocol 2 was superior to that obtained with protocol 1 (P = 0.04). Protocol 2 was superior for perigastric vessel enhancement (left gastric artery, right gastroepiploic artery, and splenic artery; P < 0.001, P < 0.001, and P = 0.001, respectively). The stomach-to-tumor CNR during the PP of protocol 2 was significantly higher than that during either the AP or PP of protocol 1 (P = 0.004 and P = 0.001, respectively). The mean rankings of the artery visualization were significantly higher with protocol 2 than with protocol 1 (P < 0.001).
CONCLUSIONS: The dual-phase scan with test bolus technology could improve the tumor CNR and had high staging accuracy for serosa-negative tumors as well as high perigastric artery enhancement, yielding satisfactory artery visualization for diagnosis.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26720202     DOI: 10.1097/RCT.0000000000000339

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  6 in total

1.  Locally advanced gastric cancer: total iodine uptake to predict the response of primary lesion to neoadjuvant chemotherapy.

Authors:  Xiaoyuan Gao; Yang Zhang; Fei Yuan; Bei Ding; Qianchen Ma; Wenjie Yang; Jing Yan; Lianjun Du; Baisong Wang; Fuhua Yan; Martin Sedlmair; Zilai Pan; Huan Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-09       Impact factor: 4.553

Review 2.  Exploring the role of molecular biomarkers as a potential weapon against gastric cancer: A review of the literature.

Authors:  Marwa Matboli; Sarah El-Nakeep; Nourhan Hossam; Alaa Habieb; Ahmed E M Azazy; Ali E Ebrahim; Ziad Nagy; Omar Abdel-Rahman
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

3.  MicroRNA-144 functions as a tumor suppressor in gastric cancer by targeting cyclooxygenase-2.

Authors:  Qiang Yao; Anxin Gu; Zhuozhong Wang; Yingwei Xue
Journal:  Exp Ther Med       Date:  2018-01-17       Impact factor: 2.447

4.  KK-LC-1 may be an effective prognostic biomarker for gastric cancer.

Authors:  Jun Ji; Jiahui Chen; Anqiang Wang; Wei Zhang; Hongge Ju; Yang Liu; Leping Li
Journal:  BMC Cancer       Date:  2021-03-12       Impact factor: 4.430

5.  Dual-Energy Computed Tomography-Based Radiomics to Predict Peritoneal Metastasis in Gastric Cancer.

Authors:  Yong Chen; Wenqi Xi; Weiwu Yao; Lingyun Wang; Zhihan Xu; Michael Wels; Fei Yuan; Chao Yan; Huan Zhang
Journal:  Front Oncol       Date:  2021-05-14       Impact factor: 6.244

6.  Predicting Chemotherapeutic Response for Far-advanced Gastric Cancer by Radiomics with Deep Learning Semi-automatic Segmentation.

Authors:  Jing-Wen Tan; Lan Wang; Yong Chen; WenQi Xi; Jun Ji; Lingyun Wang; Xin Xu; Long-Kuan Zou; Jian-Xing Feng; Jun Zhang; Huan Zhang
Journal:  J Cancer       Date:  2020-10-18       Impact factor: 4.207

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.